相关实验视频

Updated: Jul 16, 2025

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

在线适应性放射治疗癌的临床经验

Malene E Bak¹, Nikolaj K G Jensen¹, Trine J Nøttrup¹

¹Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Acta oncologica (Stockholm, Sweden)

|September 15, 2023

概括

在线适应性放射治疗改善了癌患者的目标剂量覆盖率. 这种先进的技术提高了临床目标体积 (CTV) 和计划目标体积 (PTV) 的覆盖率,在治疗期间提供了强大的收益.

科学领域:

辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

Vulvar carcinoma 放射治疗带来了诸多挑战,包括高复发风险,难以划定目标,以及潜在的辐射后果.
在线适应性放射治疗旨在改善正常组织的节约,同时保持目标覆盖范围.

研究的目的:

评估在线适应性放射疗法减少正常组织剂量的可行性.
评估在线适应性放射治疗对临床目标体积 (CTV) 覆盖率和危险器官 (OAR) 剂量的影响.

主要方法:

20名阴道癌患者使用Varian Ethos加速器在线接受了自适应性放射治疗.
每日设置CBCT被用于适应性规划,验证CBCT在剂量递送之前获得.
从计划和调整计划中分析了CTV剂量覆盖率和OAR剂量.

主要成果:

平均CTV D95%从计划计划中的98%±5%提高到调整计划中的100.0%±0.3%和100.0%±0.8% (设置和验证CBCT).
对63.5%的分量选择了适应计划;不适应的原因包括"没有显著的剂量计增益"和"MD不可用".
平均适应时间为15分钟.

结论:

与图像引导RT相比,在线自适应性放射治疗显著改善了CTV和PTV剂量覆盖率.
在整个治疗过程中,观察到的剂量计收益是强大的.

关键词:

在线适应性辐射疗法电脑辅助放射治疗计划计算机辅助放射治疗计划可变形图像的注册变形图像的注册阴道瘤的发生.工作流的工作流.

更多相关视频

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...